Clinical Trial Update: Azacitidine and Pembrolizumab in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine in combination with pembrolizumab in pancreatic cancer has completed with results posted in July 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Susan E. Bates | Conditions: Pancreas Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-07-05